Heath W. Cleaver CPA serves as Independent Director of the Company. Mr. Cleaver has served as a director of Bio-Path since 2014. Since February 2020, Mr. Cleaver has served as the President and Chief Financial Officer of Compressor Engineering Corporation (“CECO”), a privately-held independent manufacturer of engine and compressor replacement parts. Prior to his current roles, Mr. Cleaver served as Chief Financial Officer of CECO from July 2017 to February 2020. Mr. Cleaver was previously a consultant providing turn-around management and capital raising services to companies in the oil and gas service sector from 2016 to 2017. From 2015 to 2016, Mr. Cleaver served as the Chief Financial Officer of Global Fabrication Services, Inc. In 2014, Mr. Cleaver served as Chief Financial Officer at Tarka Resources, Inc. From 2011 until 2014, Mr. Cleaver served as Chief Financial Officer of Porto Energy Corp. From 2010 until 2011, Mr. Cleaver served as Chief Accounting Officer of Porto Energy Corp. Mr. Cleaver served as Corporate Controller and then as Vice President and Chief Accounting Officer for BPZ Energy from 2006 to 2010. Beginning in 1997 through 2004, Mr. Cleaver served in various accounting roles, including Financial Controller, at Horizon Offshore Contractors, Inc. Mr. Cleaver is a Certified Public Accountant in the state of Texas and holds a Bachelor’s Degree in Business Administration - Accounting from Texas A&M University.
Heath Cleaver is 46, he's been the Independent Director of Bio-Path Inc since 2014. There are 6 older and no younger executives at Bio-Path Inc. The oldest executive at Bio-Path Holdings Inc is Peter H. Nielsen MBA, 72, who is the Co-Founder, Chairman, CEO, Pres, CFO & Treasurer.
Heath's mailing address filed with the SEC is 4010 Balsam Fir Ln, Spring, TX 77386, USA.
Over the last 16 years, insiders at Bio-Path Inc have traded over $171,456 worth of Bio-Path Inc stock and bought 1,226,067 units worth $451,466 . The most active insiders traders include Capital, Llc Armistice Capi..., Thomas E Garrison, and Michael J. Garrison. On average, Bio-Path Inc executives and independent directors trade stock every 423 days with the average trade being worth of $156,477. The most recent stock trade was executed by Capital, Llc Armistice Capi... on 18 January 2019, trading 64,457 units of BPTH stock currently worth $171,456.
bio-path is a publicly traded biotechnology company focused on developing therapeutic products utilizing its proprietary dnabilize™ technology designed to distribute nucleic acid drugs throughout the human body with a simple intravenous infusion. the company’s initial focus is in oncology. bio-path’s lead product candidate, prexigebersen, (bp1001), is in phase ii clinical trials for aml in combination with ldac in elderly de novo patients. the safety segment of the phase ii trial for prexigebersen + dasatinib in blast-phase and accelerated phase cml patients is expected to begin in 2017. bio-path’s second drug candidate, bp1002, is ready for the clinic where it will be evaluated in lymphoma and solid tumors. the technology behind prexigebersen is called dnabilize™ technology. dnabilize is a liposomal antisense dna platform with two critical improvements in oligonucleotide therapeutics. the main benefits to the patient are, 1: we have never had a single patient experience thrombocytopen
Bio-Path Inc executives and other stock owners filed with the SEC include: